[Therapeutic agents for Alzheimer's disease].
Honma
A
A
D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009479:Neuropeptides / Q000627:therapeutic use; D048448:Phenylcarbamates; D010880:Piperidines / Q000627:therapeutic use; D043643:Receptor, Muscarinic M1; D011976:Receptors, Muscarinic; D000068836:Rivastigmine; D013141:Spiro Compounds; D013619:Tacrine / Q000627:therapeutic use
C067766:2,8-dimethyl-3-methylene-1-oxa-8-azaspiro(4,5)decane; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D009479:Neuropeptides; D048448:Phenylcarbamates; D010880:Piperidines; D043643:Receptor, Muscarinic M1; D011976:Receptors, Muscarinic; D013141:Spiro Compounds; D013619:Tacrine; D000077265:Donepezil; D000068836:Rivastigmine